Moreover, we explored whether targeting NINJ2 could enhance chemosensitivity and reduce relapse, providing potential for NINJ2 as a biomarker and therapeutic target to improve treatment outcomes for patients with gastric cancer. This evidence concerns the gene NINJ2 and gastric cancer.